{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000000", "text": "# ESMO_CPG_EpithelialOvarian_2023", "section": "ESMO_CPG_EpithelialOvarian_2023", "page_from": null, "page_to": null, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d1051045a433963434d26a312cb4ee901799960b2e69626b5953f27596ebacb2"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000001", "text": "SPECIAL ARTICLE\nNewly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical\nPractice Guideline for diagnosis, treatment and follow-up5\nA. González-Martín1, P. Harter2, A. Leary3, D. Lorusso4,5, R. E. Miller6,7, B. Pothuri8, I. Ray-Coquard9, D. S. P. Tan10,11,12,13,\nE. Bellet14, A. Oaknin15 & J. A. Ledermann16, on behalf of the ESMO Guidelines Committee\u0001\n1Department of Medical Oncology and Program in Solid Tumors Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid and Pamplona,\nSpain; 2Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany; 3Department of Medical Oncology, Gustave Roussy Cancer\nCenter, INSERM U981, Université Paris-Saclay, Paris, France; 4Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome;\n5Department of Woman, Child and Public Health, Catholic University of the Sacred Heart, Rome, Italy; 6Department of Medical Oncology, University College Hospital,\nLondon; 7Department of Medical Oncology, St Bartholomew’s Hospital, London, UK; 8Department of Obstetrics and Gynecology, Perlmutter Cancer Center, NYU", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2786b9874055389848e10c28a3a7b3b74985ab9b0a46977471ec8ffa305149fe"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000002", "text": "London; 7Department of Medical Oncology, St Bartholomew’s Hospital, London, UK; 8Department of Obstetrics and Gynecology, Perlmutter Cancer Center, NYU\nLangone Health, New York University School of Medicine, New York, USA; 9Department of Medical Oncology, Centre Leon Bernard and Université Claude Bernard Lyon\nI, Lyon, France; 10Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 11National University of Singapore (NUS)\nCentre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; 12Cancer Science Institute, National University of Singapore,\nSingapore; 13Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Singapore, Singapore; 14ACTOdAlleanza contro\nil Tumore Ovarico, Milan, Italy; 15Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron\nBarcelona Hospital Campus, Barcelona, Spain; 16Department of Oncology, UCL Cancer Institute, University College London, London, UK\nAvailable online 17 August 2023", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "80d9a0e339d8d6a1255f886fff515e623ae9643cb36320b090a50cb95db8052d"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000003", "text": "Barcelona Hospital Campus, Barcelona, Spain; 16Department of Oncology, UCL Cancer Institute, University College London, London, UK\nAvailable online 17 August 2023\nKey words: epithelial ovarian cancer, guideline, diagnosis, surgery, treatment, follow-up\nINCIDENCE AND EPIDEMIOLOGY\nEpithelial ovarian cancer (EOC) represents a heterogeneous\nspectrum of disease entities at a clinical, pathological and\nmolecular level. Ovarian cancer is the second most lethal\ngynaecological malignancy worldwide behind cervical can-\ncer and the ﬁrst in developed countries, with w200 000\nwomen dying globally in 2020.1 A study of epidemiological\ntrends from 1990 to 2019 showed that highly developed\nregions had the highest burden and mortality.2\nInfertility or nulliparity, estrogen hormone treatment and\nobesity have been reported as risk factors for EOC and\ncould account for the rising incidence of the disease in\ndeveloped countries.3 Oral contraceptive use, especially\nover longer periods, and breastfeeding can reduce inci-\ndence.4 A recent large study revealed signiﬁcant heteroge-\nneity of associations for 14 EOC risk factors across\nhistological subtypes.3 Higher\nparity, younger age\nat", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "89731e8955ef4469a9fae096736ff8d89e3cfac3fd145ca308687f1bf853fa8c"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000004", "text": "dence.4 A recent large study revealed signiﬁcant heteroge-\nneity of associations for 14 EOC risk factors across\nhistological subtypes.3 Higher\nparity, younger age\nat\nmenopause and tubal ligation were most strongly associ-\nated with reduced risk in endometrioid carcinomas (ECs)\nand clear-cell carcinomas (CCCs), while endometriosis was\nassociated with an increased risk in both EOC subtypes.3\nSerous and poorly differentiated carcinomas had modest\nassociations with parity and menopausal hormonal therapy\nuse and stronger associations with a family history of\novarian cancer.3 Deleterious germline BRCA1/2 mutations\n(gBRCA1/2-muts) are associated with a 16%-65% increased\nrisk of EOC, predominantly of high-grade serous histology.5\nWomen with mutations in mismatch repair genes (Lynch\nsyndrome) have a 10%-12% lifetime risk of developing EOC,\nwhich tends to be of either EC or CCC subtype.6\nDIAGNOSIS, PATHOLOGY AND MOLECULAR BIOLOGY\nDiagnostic work-up\nThere is currently no reliable screening method for ovarian\ncancer. Most women are diagnosed based on symptoms,\nwith the majority presenting at an advanced stage. Recog-\nnised\nsymptoms\ninclude\nabdominal/pelvic\npain,\ncon-", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1bd4adeebe6fb268f97cfa2b19acca3e55adeee000d32cc83f320d200c4f0e57"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000005", "text": "cancer. Most women are diagnosed based on symptoms,\nwith the majority presenting at an advanced stage. Recog-\nnised\nsymptoms\ninclude\nabdominal/pelvic\npain,\ncon-\nstipation, diarrhoea, urinary frequency, vaginal bleeding,\nabdominal distension and fatigue. In advanced disease,\nascites and abdominal masses lead to bloating, nausea,\nanorexia, dyspepsia and early satiety. Extension of disease\ninto the pleural cavities can produce effusions and respi-\nratory symptoms.\nThe standard work-up for patients suspected of having\nEOC should include detailed history and clinical examination\nwith relevant laboratory and imaging tests (Table 1). Mea-\nsurement of serum cancer antigen 125 (CA-125) aids diag-\nnosis and is elevated in w85% of patients with advanced\ndisease. CA-125 is less useful in early-stage disease, as it is\n*Correspondence to: ESMO Guidelines Committee, ESMO Head Ofﬁce, Via\nGinevra 4, CH-6900 Lugano, Switzerland\nE-mail: clinicalguidelines@esmo.org (ESMO Guidelines Committee).\n5Note: Approved by the ESMO Guidelines Committee: April 2002, last\nupdate July 2023. This publication supersedes the previously published\nversiondAnn Oncol. 2013;24(suppl 6):vi24-vi32.", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0be33f4bb89b63acefc76c215663fcca89b9ac5b89a126f3508a3a83e6d9a41c"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000006", "text": "5Note: Approved by the ESMO Guidelines Committee: April 2002, last\nupdate July 2023. This publication supersedes the previously published\nversiondAnn Oncol. 2013;24(suppl 6):vi24-vi32.\n0923-7534/© 2023 European Society for Medical Oncology. Published by\nElsevier Ltd. All rights reserved.\nVolume 34", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "79ba94cb9d7ca95347de0400226f9ff6834e7a03ed9812e181ce0c1a4042cca1"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000007", "text": "- Issue 10\n- 2023\nhttps://doi.org/10.1016/j.annonc.2023.07.011\n833", "section": "SPECIAL ARTICLE", "page_from": 1, "page_to": 1, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8b459ed6ad4ac7a642cd22c03084b4d68d5507d84cc9cb3133e965c0c7fc89ab"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000008", "text": "only elevated in w50% of International Federation of\nGynecology and Obstetrics (FIGO) stage I cases. Elevated\nCA-125 is not speciﬁc to ovarian cancer and may be\nelevated in non-gynaecological malignancies and benign\nconditions (e.g. endometriosis and ovarian cysts).7\nMeasuring serum carcinoembryonic antigen (CEA) and\ncarbohydrate antigen 19-9 levels in addition to CA-125 may\nhelp distinguish primary mucinous ovarian tumours from a\ngastrointestinal metastasis. In this scenario, endoscopies\nshould be considered, especially if the CA-125/CEA ratio is\n\u000325/1.8\nInitial imaging should comprise pelvic ultrasound (US;\ntransabdominal and/or transvaginal) and computed to-\nmography (CT) of the thorax, abdomen and pelvis to com-\nplete clinical staging and aid surgical planning. US-based\ndiagnostic models [International Ovarian Tumor Analysis\n(IOTA) Simple Rules risk model or IOTA Assessment of\nDifferent NEoplasias in the adneXa (ADNEX) model] are\npreferable to CA-125, the human epididymis protein 4 (HE4)\nor the Risk of Ovarian Malignancy Algorithm, as they are\nsuperior in distinguishing between benign and malignant\novarian tumours and performed better than the Risk of", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e072bb9631814030e720998760783d991e957b1c6d8755fbeb2a2dbd746da341"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000009", "text": "or the Risk of Ovarian Malignancy Algorithm, as they are\nsuperior in distinguishing between benign and malignant\novarian tumours and performed better than the Risk of\nMalignancy Index in a randomised controlled trial (RCT).8\nA deﬁnitive diagnosis of ovarian cancer requires patho-\nlogical examination by an expert pathologist of tumour\nsamples from either a diagnostic biopsy or, preferably, a\nsurgical specimen. An adequate amount of tissue, particu-\nlarly if neoadjuvant chemotherapy (ChT) is planned, allows\ngenetic tumour testing for therapeutic stratiﬁcation. If a\ncomplete pathological response is achieved, sufﬁcient\nviable tumour tissue may be unavailable for genetic testing\nfollowing interval cytoreductive surgery (ICS). Cytological\nassessment of ascites (in early-stage disease) and of pleural\nﬂuid (if present and safely assessable) is required to com-\nplete staging.\nPathology and molecular biology\nEOC represents the majority (w90%) of ovarian malignancies.\nThe 2020 World Health Organization (WHO) classiﬁcation\nbased on histopathology, immunohistochemistry (IHC) and\nmolecular analysis recognises at least ﬁve distinct subtypes of", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "acc8af37d1fd6756e278bab8ec81d64bb90554d08eec75b6c287eeee983c76c0"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000010", "text": "The 2020 World Health Organization (WHO) classiﬁcation\nbased on histopathology, immunohistochemistry (IHC) and\nmolecular analysis recognises at least ﬁve distinct subtypes of\nmalignant EOC: high-grade serous carcinoma (HGSC; 70% of\ncases), EC (10%), CCC (6%-10%), low-grade serous carcinoma\n(LGSC; 5%) and mucinous carcinoma (MC; 3%-4%), along with\nother rare entities including mesonephric-like carcinoma,\nmixed-cell tumour, malignant Brenner tumour, carcinosar-\ncoma and undifferentiated carcinoma.9 Each subtype repre-\nsents a distinct disease entity with a different site of origin,\npathogenesis, clinical features and prognosis. The complexity\nof subclassiﬁcation and its effect on personalised treatment\nchoice underline the importance of histological tumour typing\nby an expert gynaecological pathologist. Details of the mo-\nlecularfeaturesofHGSC, EC,CCC,LGSCand MC are provided in\nthe Supplementary Material Section 1, available athttps://doi.\norg/10.1016/j.annonc.2023.07.011. IHC staining patterns and\nmolecular features of the different subtypes are summarised\nin Table 2. Certain genomic or molecular alterations, such as\nBRCA1/2-mut\nor\nhomologous\nrecombination\ndeﬁciency", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0b8b4ce2a1b8fa07655eb97c1411be34f40bd54e6f86555d7b946b478924238b"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000011", "text": "molecular features of the different subtypes are summarised\nin Table 2. Certain genomic or molecular alterations, such as\nBRCA1/2-mut\nor\nhomologous\nrecombination\ndeﬁciency\n(HRD), are helpful in predicting the magnitude of beneﬁt of\ntargeted therapy with poly (ADP-ribose) polymerase inhibitors\n(PARPis) in high-grade tumours.10\nRecommendations\n\u0004 If EOC is suspected, diagnostic work-up should include\nserum CA-125 measurement, pelvic US by an expert\nexaminer and CT scan of the thorax, abdomen and pelvis\n[III, A].\n\u0004 Pathological diagnosis should be made according to the\n2020 WHO classiﬁcation by an expert gynaecological\npathologist [IV, A].\n\u0004 All patients with high-grade ovarian cancer should be\ntested for germline and/or somatic BRCA1/2-muts at\ndiagnosis [I, A].\n\u0004 Testing for HRD is recommended in advanced high-grade\ncancers [I, A].\nSTAGING AND RISK ASSESSMENT\nAll patients with ovarian cancer should be surgically staged\naccording to the revised 2014 FIGO staging system for EOC\n(Table 3).11 The histotype and primary site (i.e. ovary, fal-\nlopian tube or peritoneum) of the tumour should be\nestablished and recorded as part of routine staging for\ntreatment planning.", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "381ceeff27df0d219dbf2a03588b5498a6c35a67b3eedd78160b2783a54271d0"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000012", "text": "(Table 3).11 The histotype and primary site (i.e. ovary, fal-\nlopian tube or peritoneum) of the tumour should be\nestablished and recorded as part of routine staging for\ntreatment planning.\nThereisastrongprognosticlinkbetweenthedegreeofpost-\noperative residual disease and patient survival.12 Preoperative\nimaging can help predict the likelihood of suboptimal cytore-\nductive surgery.13 Extension of tumour from the omentum to\nthe spleen or liver surface (stage IIIC) should be differentiated\nfrom isolated liver or spleen parenchymal metastases (stage\nIVB). CT and positron emission tomography (PET)eCT imaging\nhave been shown to underestimate bowel or mesenteric\ninvolvement compared with surgical exploration.14 Diffusion-\nweighted magnetic resonance imaging may have better\nsensitivity than CT for detecting involvement of surgically\ncritical tumour sites including mesenteric root inﬁltration,\nsmall bowel and colon carcinomatosis.15\nWhen the disease appears suitable for cytoreduction as\nassessed by imaging, and there are no surgical or medical\nTable 1. Diagnosis of EOC\nWork-up if EOC is suspected\n\u0004 Detailed history and clinical examination\n\u0004 Serum CA-125", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "67094dfd3a823c9da46a3b292e3a89b6b4195bb41cd6da99ced9f3741e61b86f"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000013", "text": "assessed by imaging, and there are no surgical or medical\nTable 1. Diagnosis of EOC\nWork-up if EOC is suspected\n\u0004 Detailed history and clinical examination\n\u0004 Serum CA-125\n\u0004 Serum CEA and CA 19-9, in the case of MC, and endoscopy, if either or\nboth are elevated\n\u0004 Transabdominal and transvaginal US by expert examiner\n\u0004 CT of thorax, abdomen and pelvis\n\u0004 Pathological examination of adequate tumour sample from diagnostic bi-\nopsy or surgical specimen\n\u0004 Cytological assessment of pleural effusion if present\nCA 19-9, carbohydrate antigen 19-9; CA-125, cancer antigen 125; CEA, carcinoem-\nbryonic antigen; CT, computed tomography; EOC, epithelial ovarian cancer; MC,\nmucinous carcinoma; US, ultrasound.\nAnnals of Oncology\nA. González-Martín et al.\n834\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "be7f8d00f0a6a85da6ff0cdf08da159b82481acdef914734c7fecf58c74509d6"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000014", "text": "- Issue 10\n- 2023", "section": "SPECIAL ARTICLE", "page_from": 2, "page_to": 2, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e2817dc6eaff267531b67926a7522ca9be65b4d0d6cf18f509b4daa14ba9efd"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000015", "text": "contraindications, surgical staging (through midline lapa-\nrotomy or initial laparoscopy) should be carried out to\nexplore the extent of the disease in the abdomino-\nperitoneal cavity and assess the likelihood of achieving\noptimal cytoreduction (no gross visible residual disease or\ncomplete resection).\nRecommendations\n\u0004 The revised 2014 FIGO staging system for EOC should be\nused [I, A].\nMANAGEMENT OF EARLY EOC (FIGO STAGE I-II)\nFigure 1 provides a treatment algorithm for the manage-\nment of FIGO stage I-II EOC. Supplementary Table S1,\navailable at https://doi.org/10.1016/j.annonc.2023.07.011,\nprovides a summary of the beneﬁt of adjuvant systemic\ntherapy for FIGO stage I-II EOC.\nSurgery\nThe aim of surgery for early EOC is complete resection of\nthe tumour and to undertake adequate staging, including:\nTable 2. Pathology and molecular biology of EOC subtypes\nHGSC\nEC\nCCC\nLGSC\nMC\nIHC staining\np53\nAbnormal\nAbnormal/normal\nNormal\nNormal\nNormal\np16\nþ\n\u0005\n\u0005\nWT-1\nþ\n\u0005\n\u0005\nþ\n\u0005\nER\nþ/\u0005\nþ\n\u0005\nþ\n\u0005\nPAX8\nþ\nþ\nþ\n\u0005\nVimentin\nþ\nHNF1b\nþ\nCDX2\nþ\nMolecular alterations\n(decreasing prevalence\nfrom top to bottom)\nTP53\nCTNNB1\nARID1A\nKRAS\nCDKN2A\nBRCA1/2\nARID1A\nPI3KCA\nBRAF\nKRAS\nHRD\nPTEN\nPTEN\nRAF\nHER2\nKRAS\nMSI/dMMR", "section": "SPECIAL ARTICLE", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d3dc21fd1ad1abd4fb833d9989befdd50dab249b609d4abe8131d165fa5b93d0"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000016", "text": "þ\nþ\nþ\n\u0005\nVimentin\nþ\nHNF1b\nþ\nCDX2\nþ\nMolecular alterations\n(decreasing prevalence\nfrom top to bottom)\nTP53\nCTNNB1\nARID1A\nKRAS\nCDKN2A\nBRCA1/2\nARID1A\nPI3KCA\nBRAF\nKRAS\nHRD\nPTEN\nPTEN\nRAF\nHER2\nKRAS\nMSI/dMMR\nTP53 (high-grade EC)\nMSI/dMMR\nCCC, clear-cell carcinoma; CDX2, homeobox protein CDX-2; dMMR, mismatch repair deﬁciency; EC, endometrioid carcinoma; EOC, epithelial ovarian cancer; ER, estrogen receptor;\nHGSC, high-grade serous carcinoma; HNF1b, hepatocyte nuclear factor-1b; HRD, homologous recombination deﬁciency; IHC, immunohistochemistry; LGSC, low-grade serous\ncarcinoma; MC, mucinous carcinoma; MSI, microsatellite instability; PAX8, paired box gene 8; WT-1, Wilms tumour 1.\nTable 3. FIGO staging system for EOC11\nStage I: Tumour conﬁned to ovaries or fallopian tube(s)\nIA\nTumour limited to one ovary (capsule intact) or fallopian tube, without tumour on ovarian or fallopian tube surface and without malignant\ncells in the ascites or peritoneal washings\nIB\nTumour limited to both ovaries (capsules intact) or fallopian tubes, without tumour on ovarian or fallopian tube surface and without\nmalignant cells in the ascites or peritoneal washings\nIC", "section": "SPECIAL ARTICLE", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ae99a7420d227551ce48cd56c01b5be92df0a91f18a0210ce67d2e91a06103f2"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000017", "text": "IB\nTumour limited to both ovaries (capsules intact) or fallopian tubes, without tumour on ovarian or fallopian tube surface and without\nmalignant cells in the ascites or peritoneal washings\nIC\nTumour limited to one or both ovaries or fallopian tubes, with any of the following:\nIC1\nSurgical spill\nIC2\nCapsule ruptured before surgery or tumour on ovarian or fallopian tube surface\nIC3\nMalignant cells in the ascites or peritoneal washings\nStage II: Tumour involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer\nIIA\nExtension and/or implants on uterus and/or fallopian tubes and/or ovaries\nIIB\nExtension to other pelvic intraperitoneal tissues\nStage III: Tumour involves one or both ovaries or fallopian tubes or primary peritoneal cancer, with cytologically or histologically conﬁrmed spread to the\nperitoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes\nIIIA1\nPositive retroperitoneal lymph nodes only (cytologically or histologically proven):\nIIIA1(i)\nMetastasis \u000310 mm in greatest dimension\nIIIA1(ii)\nMetastasis >10 mm in greatest dimension\nIIIA2", "section": "SPECIAL ARTICLE", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e9958ac065a492e06d5c3d5b79f2f4a654c09f8770a5fb9a9df0147e7b8267e4"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000018", "text": "IIIA1\nPositive retroperitoneal lymph nodes only (cytologically or histologically proven):\nIIIA1(i)\nMetastasis \u000310 mm in greatest dimension\nIIIA1(ii)\nMetastasis >10 mm in greatest dimension\nIIIA2\nMicroscopic extra-pelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes\nIIIB\nMacroscopic peritoneal metastasis beyond the pelvis \u00032 cm in greatest dimension, with or without metastasis to the retroperitoneal\nlymph nodes\nIIIC\nMacroscopic peritoneal metastasis beyond the pelvis >2 cm in greatest dimension, with or without metastasis to the retroperitoneal\nlymph nodes (includes extension of tumour to capsule of liver and spleen without parenchymal involvement of either organ)\nStage IV: Distant metastasis excluding peritoneal metastases\nIVA\nPleural effusion with positive cytology\nIVB\nParenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the\nabdominal cavity)\nEOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics.\nReprinted from Mutch DG, et al.11 with permission from Elsevier.\nA. González-Martín et al.\nAnnals of Oncology\nVolume 34", "section": "SPECIAL ARTICLE", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "fdb617efed35f2a3731ee0f5244ad05b11b606ac10f90140ce645dfda24d0a59"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000019", "text": "- Issue 10\n- 2023\nhttps://doi.org/10.1016/j.annonc.2023.07.011\n835", "section": "SPECIAL ARTICLE", "page_from": 3, "page_to": 3, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "705f3587e35c22fd8b5c2c2978a3c886da4cdbc2274d6a62fc79a4a581cbd64b"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000020", "text": "\u0004 Midline laparotomy\n\u0004 Inspection and palpation of the whole abdominal cavity\n\u0004 Peritoneal washing with cytological examination\n\u0004 Biopsies from all visible lesions and all abdominal ﬁelds\n\u0004 Bilateral salpingo-oophorectomy\n\u0004 Hysterectomy\n\u0004 Omentectomy\n\u0004 Appendicectomy in MC\n\u0004 Systematic pelvic and para-aortic lymphadenectomy\nWhether a laparoscopic approach is a safe alternative to\nmidline laparotomy is being debated, but as prospective\ntrials are lacking and the risk of capsule rupture increases,16\nmidline laparotomy remains the standard procedure. Sur-\ngical staging will provide prognostic information and deﬁne\nwhether ChT is needed.\nThe availability of an intra-operative frozen section to\nidentify a malignant epithelial cancer may allow the\nappropriate surgical staging to be done without the need\nfor a second operative procedure. Depending on the his-\ntological grade and subtype, \u000360% of patients with\napparent early EOC will be upstaged after comprehensive\nsurgical staging, which can impact progression-free survival\n(PFS) and overall survival (OS).17,18\nSystematic pelvic and para-aortic lymphadenectomy for\nstaging purposes is recommended for high-grade histol-", "section": "SPECIAL ARTICLE", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6c1890164a41d95db2aa434adaad9fe74bf06ce27fdd5675addac18dbe3d4a07"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000021", "text": "(PFS) and overall survival (OS).17,18\nSystematic pelvic and para-aortic lymphadenectomy for\nstaging purposes is recommended for high-grade histol-\nogies. The rate of lymph node metastases in patients with\nlow-grade EC or expansile MC is <1%.19 Therefore, lym-\nphadenectomy could be omitted in patients with these\nsubtypes and with radiologically and clinically negative\nnodes. Further information on the role of lymphadenec-\ntomy in stage I EOC is provided in the Supplementary\nMaterial Section 2, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nFertility-sparing surgery can be considered in young pa-\ntients, but always after full discussion with the patient\nabout potential risks. Patients with any stage IA histotype\nor stage IC1-2 with unilateral ovarian involvement and\nfavourable histology (i.e. low-grade tumours) would be\namenable to contralateral ovary and uterus preservation, in\ncombination with the other recommended surgical staging\nprocedures.20\nSystemic therapy\nAdjuvant platinum-based ChT signiﬁcantly prolongs OS and\nPFS in patients with early-stage EOC, as demonstrated in\nthe joint analysis of ACTION and ICON1 trials and a", "section": "SPECIAL ARTICLE", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "87bde54350e66221e07ab122c8de2484c8680e87a9d9251ff57be49055d93f42"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000022", "text": "procedures.20\nSystemic therapy\nAdjuvant platinum-based ChT signiﬁcantly prolongs OS and\nPFS in patients with early-stage EOC, as demonstrated in\nthe joint analysis of ACTION and ICON1 trials and a\nFigure 1. Management of early EOC (FIGO stage I-II).\nSee Supplementary Table S1, available at https://doi.org/10.1016/j.annonc.2023.07.011, for a summary of the beneﬁt of adjuvant systemic therapy for early EOC (FIGO\nI-II stage).\nPurple: general categories or stratiﬁcation; red: surgery; blue: systemic anticancer therapy; white: other aspects of management; dashed lines: optional therapy.\nCCC, clear-cell carcinoma; ChT, chemotherapy; EC, endometrioid carcinoma; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics;\nHGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; MC, mucinous carcinoma.\nAnnals of Oncology\nA. González-Martín et al.\n836\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34", "section": "SPECIAL ARTICLE", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a33b07a7e6e39cf22fbdaf0e5376186aea449dd745db9b2c161ec826519f28f1"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000023", "text": "- Issue 10\n- 2023", "section": "SPECIAL ARTICLE", "page_from": 4, "page_to": 4, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e2817dc6eaff267531b67926a7522ca9be65b4d0d6cf18f509b4daa14ba9efd"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000024", "text": "Cochrane\nsystematic\nreview.21-23\nAn updated analysis\nshowed the beneﬁt of adjuvant ChT largely depended on\nhistological subtype (see Figure 1 and Supplementary\nTable S1, available at https://doi.org/10.1016/j.annonc.\n2023.07.011).22 A large Surveillance, Epidemiology and\nEnd\nResults\nseries\nof\nstage\nI\nEC\ndemonstrated\nno\nimprovement in grade 1-2 EC.24 In CCC, retrospective\nstudies of an Asian population did not identify any beneﬁt\nwith adjuvant ChT for early-stage disease (stage IA-IC1).25 In\nstage I MC, adjuvant ChT may be avoided for either\nexpansile subtype or grade 1 inﬁltrative based on the\nexcellent prognosis.26\nThe standard adjuvant ChT consists of six cycles of\nplatinum-based ChT. A Gynecologic Oncology Group (GOG)\ntrial\ncomparing\nthree\nversus\nsix\ncycles\nof\nadjuvant\npaclitaxelecarboplatin did not identify a signiﬁcant reduc-\ntion in recurrence risk with longer treatment, but additional\ntoxicity occurred.27 Only serous carcinoma seems to beneﬁt\nfrom longer adjuvant therapy compared with non-serous\ntumours.28 The optimal ChT regimen (platinum alone or a\nplatinum-based combination) is not completely resolved.22\nRecommendations", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "791beb2b5a1b832150f29d625eb3aa00abb83fdb9da1ab8968ec5450a2664e9a"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000025", "text": "from longer adjuvant therapy compared with non-serous\ntumours.28 The optimal ChT regimen (platinum alone or a\nplatinum-based combination) is not completely resolved.22\nRecommendations\n\u0004 Surgical staging is recommended in presumed early-stage\novarian cancer for classiﬁcation and recommendation of\noptimal systemic therapy [III, A].\n\u0004 Adjuvant ChT in early-stage ovarian cancer is generally\nrecommended for FIGO stage I-IIB (see exceptions\nbelow) [II, A], either paclitaxelecarboplatin [I, B] or car-\nboplatin (six cycles) alone [I, A].\n\u0004 For patients receiving paclitaxelecarboplatin, a mini-\nmum of three cycles are recommended except for\nHGSC/high-grade EC or any stage IC-II regardless of histo-\ntype, for which six cycles are suggested [II, B].\n\u0004 The beneﬁt of adjuvant ChT is uncertain and can be\nconsidered as optional [III, C] for:\no LGSC stage IB-IC\no CCC stage IA-IC1\no Low-grade EC stage IB-IC\no Expansile MC stage IC\no Inﬁltrative MC stage IA\n\u0004 Adjuvant ChT is not recommended in completely staged\npatients with LGSC stage IA, low-grade EC stage IA or\nexpansile MC stage IA-IB [II, E].\nMANAGEMENT OF ADVANCED EOC (FIGO STAGE III-IV)\nSurgery", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "1e162ee506ade0d6ca24ce0d082cd913a860ba09958c2973451e97685f8c5173"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000026", "text": "\u0004 Adjuvant ChT is not recommended in completely staged\npatients with LGSC stage IA, low-grade EC stage IA or\nexpansile MC stage IA-IB [II, E].\nMANAGEMENT OF ADVANCED EOC (FIGO STAGE III-IV)\nSurgery\nIn advanced EOC, surgery aims to achieve a complete or\noptimal cytoreduction, deﬁned as total macroscopic tumour\nclearance with no residual visible disease, since this has\nbeen shown to signiﬁcantly increase OS and PFS.12 This\nneeds maximal surgical effort and may require intestinal\nresection, diaphragmatic and peritoneal stripping, splenec-\ntomy and removal of bulky para-aortic lymph nodes and, in\nsome cases, extra-abdominal disease.29 An increasing body\nof evidence suggests that surgical expertise and specialist\ntraining result in improvements in the rate of complete\ncytoreduction. Thus, patients with advanced disease are\nadvised to undergo surgery in specialised centres with\nadequate infrastructure and trained teams.30 Patients with\nmacroscopic complete resection and clinically negative\nnodes do not beneﬁt from systematic lymphadenectomy,\nwhich unnecessarily increases the rate of post-operative\ncomplications and mortality.31\nThe timing of surgical cytoreduction in relation to ChT is", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "472168ad213de63a0644d10bbd860facc51150aae5d2ecffcf8c4e2b538f7c39"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000027", "text": "nodes do not beneﬁt from systematic lymphadenectomy,\nwhich unnecessarily increases the rate of post-operative\ncomplications and mortality.31\nThe timing of surgical cytoreduction in relation to ChT is\nstill debated. The gold standard in patients with stage III-IV\ndisease is primary cytoreductive surgery (PCS), if physically\nable to undergo surgery and complete resection seems\nachievable, followed by systemic treatment (Figure 2). PCS\nis also recommended in patients with less chemosensitive\nsubtypes (e.g. MC or LGSC), even if uncertainty about\nachieving complete resection exists and a small residual\ntumour (<1 cm) is likely to remain.32\nProspective trials have shown that three cycles of\nplatinum-based neoadjuvant ChT (NACT) followed by ICS\nand completion of ChT was not inferior to PCS followed by\nChT in patients with advanced bulky stage IIIC or IV disease,\nfor whom complete resection at primary surgery is unlikely\nor extensive surgery is not tolerable due to frailty or other\nsigniﬁcant comorbidities.33,34 In all neoadjuvant trials,\nhowever, the PFS and OS were lower than in primary sur-\ngery trials. Due to the limitations of randomised NACT trials,", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e817547c0d15c7991dd93bb7cad55891041262a460e343d577c6bbfd1e54ecdb"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000028", "text": "signiﬁcant comorbidities.33,34 In all neoadjuvant trials,\nhowever, the PFS and OS were lower than in primary sur-\ngery trials. Due to the limitations of randomised NACT trials,\nit is not yet determined whether NACT and ICS could be an\noption for patients for whom complete resection at primary\nsurgery seems feasible. This is being addressed in the\nTRUST/ENGOT-OV33/Arbeitsgemeinschaft\nGynäkologische\nOnkologie (AGO)-OVAR OP.7 trial (NCT02828618).\nSystemic therapy\nSystemic ChT after surgery is recommended for all advanced\novarian cancer, and consideration should be given to the\ninclusion of antiangiogenic and maintenance therapies\n(Figure 2).\nChT. Standard ChT consists of six cycles of paclitaxel (175\nmg/m2)ecarboplatin [area under the curve (AUC) 5-6]\nintravenously (i.v.) every 3 weeks.35 Prolonging ChT for\nmore than six cycles or adding a third drug does not result\nin a better outcome.36 For patients with contraindications\nto paclitaxel (i.e. allergy, neuropathy or intolerance),\ncombining carboplatin with docetaxel or pegylated lipo-\nsomal\ndoxorubicin\n(PLD)\ncan\nbe\nconsidered\nas\nan\nalternative.37,38\nThe improved PFS and OS seen in the Japanese dose-\ndense\nChT\ntrial39\nusing\nweekly", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "17f3cadb2d1adcbe22e60284445988396e9b2793e24716816f0879968116754a"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000029", "text": "somal\ndoxorubicin\n(PLD)\ncan\nbe\nconsidered\nas\nan\nalternative.37,38\nThe improved PFS and OS seen in the Japanese dose-\ndense\nChT\ntrial39\nusing\nweekly\npaclitaxel\nwas\nnot\nconﬁrmed in a further three randomised trials (GOG-262,40\nICON841 and MITO-742). Outcomes were similar and ICON8\ndid not show differences in quality of life (QoL).43 An\nimproved QoL, however, was seen in MITO-7 using weekly\ncarboplatin (AUC 2) and a lower weekly paclitaxel dose\n(60 mg/m2), making this regimen a potential alternative for\nmore frail patients.\nA. González-Martín et al.\nAnnals of Oncology\nVolume 34", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9871fbd8da93dd5c21863f995394ad30991ab74c206356541f2bad180af2870a"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000030", "text": "- Issue 10\n- 2023\nhttps://doi.org/10.1016/j.annonc.2023.07.011\n837", "section": "Cochrane", "page_from": 5, "page_to": 5, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7be0c752896de94adcfa023d56f21a5f25542e602e55af2b2c1c6b71f2a17f11"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000031", "text": "Figure 2. Management of advanced EOC (FIGO stage III-IV).\nPurple: general categories or stratiﬁcation; red: surgery; blue: systemic anticancer therapy; turquoise: combination of treatments or other systemic treatments; white:\nother aspects of management.\nAUC, area under the curve; ChT, chemotherapy; EMA, European Medicines Agency; EOC, epithelial ovarian cancer; ESCAT, ESMO Scale for Clinical Actionability of\nmolecular Targets; FDA, Food and Drug Administration; FIGO, International Federation of Gynecology and Obstetrics; HRD, homologous recombination deﬁciency;\nMCBS, ESMO-Magnitude of Clinical Beneﬁt Scale; PARPi, poly (ADP-ribose) polymerase inhibitor; wt, wild type.\naESMO-MCBS v1.1104 was used to calculate scores for new therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESMO-MCBS\nWorking Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).\nbWeekly ChT with paclitaxel (60 mg/m2)ecarboplatin (AUC 2) can be an alternative in frail patients [I, B].", "section": "Cochrane", "page_from": 6, "page_to": 6, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2fdb8ad29a26d908aeacba48e030760b43de232257ad5a9c2f5ea266f35aebcf"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000032", "text": "bWeekly ChT with paclitaxel (60 mg/m2)ecarboplatin (AUC 2) can be an alternative in frail patients [I, B].\ncOnly when patients have complete or partial response to platinum or no evidence of disease. For patients without response to platinum, a PARPi is not indicated; these\npatients can be managed with bevacizumab maintenance if appropriate (mainly stable disease), or with second-line therapy if they have progressive disease (see\nFigure 3).\ndESCAT scores apply to alterations from genomic-driven analyses only. These scores have been deﬁned by the guideline authors, assisted if needed by the ESMO\nTranslational Research and Precision Medicine Working Group.103 See Supplementary Table S3, available at https://doi.org/10.1016/j.annonc.2023.07.011, for more\ninformation on ESCAT scores.\neOption for patients for whom bevacizumab was added to paclitaxelecarboplatin.\nAnnals of Oncology\nA. González-Martín et al.\n838\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34", "section": "Cochrane", "page_from": 6, "page_to": 6, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f86a7e7f680fb4326e47add2a1da92d7dc19779ab77fc3c2bf3d294a77a12f04"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000033", "text": "- Issue 10\n- 2023", "section": "Cochrane", "page_from": 6, "page_to": 6, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e2817dc6eaff267531b67926a7522ca9be65b4d0d6cf18f509b4daa14ba9efd"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000034", "text": "A meta-analysis of ﬁve randomised trials44 using post-\noperative intraperitoneal (i.p.) ChT reported a beneﬁt in\nPFS and OS compared with i.v. ChT regimens in patients\nwith a small volume (<1 cm) or no residual disease after\nsurgery. Nevertheless, the negative results of the GOG-252\ntrial (a large randomised phase III trial comparing two\ni.p. platinum-based regimens, i.p. carboplatin AUC 6 or i.p.\ncisplatin 75 mg/m2, with i.v. administration combined with\nbevacizumab),45 together with the greater toxicity and\ncomplexity of i.p. administration, have led to the decline of\nthis strategy as a standard of care.\nHyperthermic i.p. perioperative ChT (HIPEC) in ﬁrst line\nhas been explored in OVHIPEC, a randomised phase III trial\ncomparing NACT followed by ICS with or without HIPEC.46\nThe trial showed signiﬁcantly longer PFS and OS without\nincreased toxicity with HIPEC. Nevertheless, an imbalance\nof prognostic factors such as tumour histotype, the lack of\nstratiﬁcation based on well-recognised prognostic factors\nsuch as tumour BRCA1/2-mut and HRD status and the\nlimited sample size made it very difﬁcult to extrapolate\nthese results. In another randomised trial, HIPEC did not", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ab7d1947622c18f21e839924086d45f343b75123f16f01a5703c9f1a7fd1d876"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000035", "text": "such as tumour BRCA1/2-mut and HRD status and the\nlimited sample size made it very difﬁcult to extrapolate\nthese results. In another randomised trial, HIPEC did not\nshow survival superiority over standard treatment.47 Given\nthese concerns, HIPEC continues to be an area of research\nand should not be considered as standard therapy.\nAntiangiogenic therapy in the ﬁrst line. Bevacizumab is a\nmonoclonal antibody targeting vascular endothelial growth\nfactor (VEGF). Two large RCTs, GOG-21848 and ICON7,49\nshowed that the addition of bevacizumab to paclitaxele\ncarboplatin ﬁrst-line therapy followed by bevacizumab as\nmaintenance resulted in a statistically signiﬁcant increase in\nPFS versus ChT alone, but without an OS beneﬁt. A post hoc\nsubgroup analysis suggested a greater beneﬁt in PFS and OS\nin the clinical ‘high-risk’ population (deﬁned as patients\nwith stage III and macroscopic residual tumour >1 cm or\nstage IV).50 In ICON7 the dose of bevacizumab was 7.5 mg/\nkg and the duration of treatment was shorter (12 months).\nAlthough this lower dose is used by some, the licensed dose\nof bevacizumab is 15 mg/kg given for 15 months in com-\nbination with ﬁrst-line paclitaxelecarboplatin ChT to pa-", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "18b231eb88782ce2391bc9fd2e66a78ea43b7d332ce293e7a4c881c276c4d64f"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000036", "text": "Although this lower dose is used by some, the licensed dose\nof bevacizumab is 15 mg/kg given for 15 months in com-\nbination with ﬁrst-line paclitaxelecarboplatin ChT to pa-\ntients with stage IIIB-IV (FIGO 1988 classiﬁcation) ovarian\ncancer, regardless of histology. In the ENGOT-OV15 study, a\nlonger duration of bevacizumab administration (30 versus\n15 months) did not improve PFS.51\nBevacizumab in combination with NACT has been\nexplored in two small randomised trials, ANTHALYA and\nGEICO 1205/NOVA.52,53 Although no increase in grade 3-4\ntoxicities compared with ChT alone was reported, the po-\ntential beneﬁt of two to three doses of bevacizumab before\nICS is debatable due to its lack of impact on complete\nresection rate and PFS.\nHRD and PARPis. Up to 50% of HGSCs are detected as HRD-\npositive with current tests. Included in these are 15%-20% of\ngBRCA1/2-mut cases. Somatic BRCA1/2-muts, epigenetic\nsilencing via hypermethylation of the BRCA1 promoter and\ndeﬁciency in other proteins and pathways involved in the\nhomologous recombination repair of DNA double-strand\nbreaks contribute to the remainder of positive tests.54 HRD\npositivity with or without BRCA1/2-mut is a well-established", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "64f01906b083d2e1a481f84448dc30cd885ef378a55ae3b33940dab3461521ad"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000037", "text": "homologous recombination repair of DNA double-strand\nbreaks contribute to the remainder of positive tests.54 HRD\npositivity with or without BRCA1/2-mut is a well-established\npredictive factor of the magnitude of response to PARPis.\nThe incorporation of PARPis as maintenance after ﬁrst-line\nChT has led to a new era in the ﬁrst-line management of\nadvanced HGSC/high-grade EC with unprecedented beneﬁt in\npatients with BRCA1/2-mutated or BRCA1/2-wild type (wt)/\nHRD-positive tumours. Supplementary Material Section 3,\navailable\nat\nhttps://doi.org/10.1016/j.annonc.2023.07.011,\nprovides detailed information on the SOLO1,55 PAOLA-1/\nENGOT-OV2556 and PRIMA/ENGOT-OV26/GOG-301257 trials,\nwhich led to the approval of olaparib in BRCA1/2-mutated\ntumours, olaparibebevacizumab in HRD-positive tumours and\nniraparib regardless of biomarker status of the tumour,\nrespectively. The results of the ATHENA-MONO/GOG-3020/\nENGOT-OV4558 and VELIA59 trials with rucaparib and veliparib,\nrespectively, are also described.\nA descriptive OS analysis of SOLO1 at 7-year follow-up60\nand the ﬁnal OS analysis of PAOLA-161 have shown a beneﬁt\nin OS for olaparib in patients with BRCA1/2-mutated tu-", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "d70fd1eca704d16a0e6d623ecbe8bff9869659e51971cb023c8a47a683ddb684"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000038", "text": "A descriptive OS analysis of SOLO1 at 7-year follow-up60\nand the ﬁnal OS analysis of PAOLA-161 have shown a beneﬁt\nin OS for olaparib in patients with BRCA1/2-mutated tu-\nmours and olaparibebevacizumab in patients with HRD-\npositive tumours regardless of BRCA1/2-mut status (see\nSupplementary Material Section 3, available at https://doi.\norg/10.1016/j.annonc.2023.07.011).\nNon-high-grade serous advanced ovarian cancer. Pacli-\ntaxelecarboplatin is the standard systemic ChT used in\nLGSC, CCC and MC. Multiple retrospective studies, however,\nshowed lower response rates in these histotypes compared\nwith HGSC.62-64 Bevacizumab has shown activity in all his-\ntotypes including those less chemoresponsive, e.g. LGSC or\nCCC.49 The majority of LGSCs have high expression of es-\ntrogen receptor (ER) and progesterone receptor (PgR);\nretrospective studies suggest a possible therapeutic value of\nhormone therapy in the maintenance of newly diagnosed\nadvanced LGSC.65 This intervention is currently under\nevaluation in a prospective RCT (NCT04095364).\nRecommendations\n\u0004 Patients with advanced EOC should be evaluated for PCS\nby a specialised team, with the aim of achieving", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4e6d8aa4fe4f4fc29642e24af3c94bcadc9c5601fee0b6fe9e28cf8c30bf546c"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000039", "text": "evaluation in a prospective RCT (NCT04095364).\nRecommendations\n\u0004 Patients with advanced EOC should be evaluated for PCS\nby a specialised team, with the aim of achieving\ncomplete cytoreduction (absence of all visible residual\ndisease) [III, A].\n\u0004 When complete cytoreductive surgery is feasible, PCS is\nrecommended [III, A]; otherwise, obtaining adequate bi-\nopsy tissue for histology and molecular testing is recom-\nmended [III, A].\n\u0004 When complete cytoreductive surgery is not feasible,\nNACT for three cycles followed by ICS and three cycles\nof paclitaxelecarboplatin are recommended [I, A].\n\u0004 Bevacizumab in the neoadjuvant setting, before ICS, can\nbe considered [II, B].\n\u0004 When ICS is not possible, and in the absence of overt dis-\nease progression, three additional cycles of paclitaxele\ncarboplatin alone [I, A] or with bevacizumab [II, B] are\nrecommended.\n\u0004 Systemic therapy decisions should be informed by\nBRCA1/2-mut (germline and/or somatic) and HRD status\ntesting carried out at primary diagnosis [I, A].\nA. González-Martín et al.\nAnnals of Oncology\nVolume 34", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "131db9962c7d05c889364388df675534457c2aea1714fa4ffd260ab8262ce0e7"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000040", "text": "- Issue 10\n- 2023\nhttps://doi.org/10.1016/j.annonc.2023.07.011\n839", "section": "Cochrane", "page_from": 7, "page_to": 7, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0dabb7be47b7d1b49eba43c9ae6c422b127a2b89b09a9070b01d2139504d60f1"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000041", "text": "\u0004 Paclitaxel (175 mg/m2)ecarboplatin (AUC 5-6) every 3\nweeks for six cycles is the standard ﬁrst-line ChT in\nadvanced ovarian cancer [I, A].\n\u0004 The schedule of weekly ChT with paclitaxel (60 mg/m2)e\ncarboplatin (AUC 2) can be considered as an alternative\nin frail patients [I, B].\n\u0004 Bevacizumab improves PFS in patients with stage III-IV\novarian cancer and should be considered in addition to\npaclitaxelecarboplatin\n[I,\nA;\nEuropean\nSociety\nfor\nMedical Oncology-Magnitude of Clinical Beneﬁt Scale\n(ESMO-MCBS) v1.1 score: 3; MCBS v1.1 score: 4 in\nhigh-risk patients].\n\u0004 Given the controversy about i.p. ChT [I, E] and HIPEC\n[II, D], they are not considered a standard of care in\nﬁrst-line treatment.\n\u0004 Maintenance treatment with PARPis, with or without\nbevacizumab,\nis\nrecommended\nfor\npatients\nwith\nBRCA1/2-mutated or BRCA1/2-wt/HRD-positive tumours\nwith no evidence of disease at the end of ChT or a com-\nplete or partial response to platinumepaclitaxel ﬁrst-line\nChT [I, A].\no For BRCA1/2-mutated: olaparib for 2 years [ESMO-\nMCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity of molecular Targets (ESCAT) score: I-A], niraparib\nfor 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score:", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "426c56fee58bf024418c33c47c746c9d8d7ae6ab54ce04b27b7a051b0658ab89"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000042", "text": "MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity of molecular Targets (ESCAT) score: I-A], niraparib\nfor 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score:\nI-A] or olaparibebevacizumab for 2 years [ESMO-\nMCBS v1.1 score: 3; ESCAT score: I-A].\no For BRCA1/2-wt/HRD-positive: niraparib for 3 years\n[ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or\nolaparibebevacizumab for 2 years [ESMO-MCBS v1.1\nscore: 3; ESCAT score: I-A).\n\u0004 Maintenance treatment with either bevacizumab [I, A] or\nniraparib for 3 years [I, B; ESMO-MCBS v1.1 score: 3] can\nbe recommended for HRD-negative tumours, with the\nlatter\nfollowing\ncomplete\nor\npartial\nresponse\nto\nplatinumepaclitaxel ﬁrst-line ChT. The choice of treat-\nment should be based on disease and clinical character-\nistics of the patient.\n\u0004 Maintenance with anti-estrogen therapy after ﬁrst-line\nplatinum-based ChT can be considered in LGSC [IV, B].\nMANAGEMENT OF RECURRENT EOC\nPatient assessment\nUp to 70% of patients with stage III-IV high-grade ovarian\ncancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "2ab4a7b43f004a94cce9cad6872aa39b2c13b513d6d2af33451216103aaee494"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000043", "text": "cancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a\ntreatment for patients with recurrent disease (Figure 3).\nSystemic therapy of recurrent disease is based on plat-\ninum-containing\nor\nnon-platinum-containing\nregimens.\nThere are currently no molecular biomarkers to predict ef-\nﬁcacy of platinum rechallenge. The deﬁnition of platinum\nsensitivity based on a 6-month cut-off of treatment-free\ninterval from last platinum (TFIp) was challenged during\nthe Fifth Gynecological Cancer InterGroup (GCIG) Ovarian\nCancer Consensus Conference and later discontinued in\nclinical practice following the 2018 ESMOeEuropean Soci-\nety of Gynaecological Oncology (ESGO) Consensus Confer-\nence, as many factors may inﬂuence TFIp (e.g. the\nfrequency of follow-up and interval of diagnostic tests) and\nthe response to platinum (i.e. histotype or BRCA1/2-mut\nstatus).32,66 Not all patients with TFIp >6 months respond\nto platinum (objective response rate 47.2%-66%),32 and\nconversely, platinum-based combinations have demon-\nstrated activity in patients with TFIp <6 months.67\nSurgery for relapse", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f4d4b0d420fd8471602b35905932f3789cc33a866c3ca8085a8d32cf4fdaf97d"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000044", "text": "to platinum (objective response rate 47.2%-66%),32 and\nconversely, platinum-based combinations have demon-\nstrated activity in patients with TFIp <6 months.67\nSurgery for relapse\nThe role of surgery for patients with a ﬁrst relapse >6\nmonths after the end of platinum-based ChT in the ﬁrst line\nwas addressed by one non-randomised trial and three\nprospective randomised trials.68-71\nThe DESKTOP series deﬁned the AGO score to identify\npatients for whom complete resection is feasible. In pa-\ntients with a positive AGO scoreddeﬁned as having com-\nplete resection at primary surgery (alternatively FIGO stage\nI-II),\ngood\nperformance\nstatus\n(Eastern\nCooperative\nOncology Group 0) and absence of ascites (<500 ml)dthe\nlikelihood of achieving a complete resection is 76%.68\nSubsequently, DESKTOP III demonstrated a beneﬁt in OS\nand PFS for patients with positive AGO scores randomised\ninto secondary cytoreductive surgery followed by platinum-\nbased ChT versus ChT alone.69\nThe SOC-1 trial had a similar design, but patients were\nselected according to the iModel. This trial was also positive\nfor PFS, but OS data are still immature.70\nThe GOG-0213 trial did not show a superiority with", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "0ebf5fe0080ef6f09138f97d6a7f808e87b756959b61ece52d083a45d842d06e"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000045", "text": "selected according to the iModel. This trial was also positive\nfor PFS, but OS data are still immature.70\nThe GOG-0213 trial did not show a superiority with\nrespect to surgery.71 Although many explanations have\nbeen proposed, the most convincing is the absence of\nobjective selection criteria for surgery.\nSystemic therapy when platinum is an option\nPatients should be considered for platinum-based therapy\nat relapse if platinum is not contraindicated and there is a\nreasonable likelihood that the patient may beneﬁt from\nplatinum rechallenge (no progression during platinum-\nbased therapy or shortly thereafter) (Figure 3).\nChT options. A meta-analysis of randomised trials comparing\ncarboplatin-based doublet ChT with carboplatin mono-\ntherapy demonstrated a beneﬁt in PFS and OS.72 Current\npartners for combination therapy with carboplatin include\npaclitaxel, gemcitabine or PLD,73-75 and the selection should\nbe based on safety proﬁle and patient preference. Based on\nsafety proﬁle, the combination of carboplatinePLD is\nconsidered the preferred option.75 If combination therapy is\ncontraindicated, carboplatin monotherapy remains an option.", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7b6d8bb914ccd4a887225a30db6e275b4f1e38b173a4c5a9840b20ee4e8f46d3"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000046", "text": "safety proﬁle, the combination of carboplatinePLD is\nconsidered the preferred option.75 If combination therapy is\ncontraindicated, carboplatin monotherapy remains an option.\nTreatment is usually recommended for four to six cycles.\nPlatinum hypersensitivity reactions (HSRs) affect w5% of\nthe general cancer population. Several outpatient-based\nplatinum ‘desensitisation’ protocols exist for gynaecological\noncology patients with HSRs that permit the successful re-\nintroduction of platinum-based therapy (carboplatin or\ncisplatin) after patients have experienced HSRs.76\nAnnals of Oncology\nA. González-Martín et al.\n840\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9f9a48124885fc38713db6308db531723236bd79304b56590cc2570150ab6902"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000047", "text": "- Issue 10\n- 2023", "section": "Cochrane", "page_from": 8, "page_to": 8, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e2817dc6eaff267531b67926a7522ca9be65b4d0d6cf18f509b4daa14ba9efd"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000048", "text": "In the absence of contraindications to platinum, there is\nno role for a non-platinum-based combination at ﬁrst\nrelapse, as was demonstrated by the lack of improvement in\nOS in the randomised phase III INOVATYON trial, which\ncompared trabectedinePLD with carboplatinePLD in a\nsubgroup of patients with a TFIp of 6-12 months.77\nAntiangiogenic therapy. Bevacizumab is approved in com-\nbination with platinum-based combination therapy and\nthen as maintenance therapy in patients with a TFIp >6\nmonths. Bevacizumab with platinum combinations (either\npaclitaxel or gemcitabine followed by bevacizumab main-\ntenance) leads to a signiﬁcant beneﬁt in objective response\nrate and PFS.71,78 OS was similar in both arms, partially\nexplained by the high rate of crossover to bevacizumab in\nsubsequent\nlines\nof\ntherapy.78\nPLDecarboplatinebev-\nacizumab has demonstrated a statistically signiﬁcant PFS\nand OS advantage compared with carboplatinegemcita-\nbineebevacizumab, making the former combination the\npreferred option if a carboplatin-based doublet with bev-\nacizumab is selected.79\nA\nrechallenge\nof\nbevacizumab\ncombined\nwith\na\ncarboplatin-based doublet is associated with a signiﬁcant", "section": "Cochrane", "page_from": 9, "page_to": 9, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "b4abd47d924e89fc59d86525f7da441d5ce6cb42a211290e62bc45df9193e168"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000049", "text": "preferred option if a carboplatin-based doublet with bev-\nacizumab is selected.79\nA\nrechallenge\nof\nbevacizumab\ncombined\nwith\na\ncarboplatin-based doublet is associated with a signiﬁcant\nimprovement in median PFS compared with ChT alone in\npatients previously treated with bevacizumab and having\nrelapsed with TFIp >6 months.80 Bevacizumab rechallenge\nhas not been licensed in Europe, however, and is, therefore,\nnot widely available.\nFigure 3. Management of recurrent EOC.\nPurple: general categories or stratiﬁcation; red: surgery; blue: systemic anticancer therapy; turquoise: combination of treatments or other systemic treatments; white:\nother aspects of management.\nAGO, Arbeitsgemeinschaft Gynaekologische Onkologie; BSC, best supportive care; EMA, European Medicines Agency; EOC, epithelial ovarian cancer; FDA, Food and\nDrug Administration; MCBS, ESMO-Magnitude of Clinical Beneﬁt Scale; mut, muation; PARPi, poly (ADP-ribose) polymerase inhibitor; PLD, pegylated liposomal doxo-\nrubicin; TFIp, treatment-free interval from last platinum.\naPatient choice and quality-of-life issues may also suggest that platinum is not the best option.", "section": "Cochrane", "page_from": 9, "page_to": 9, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "587dbeb7abf7369e4a97e423aafe218f03901f4a98f321c011aa03d21eb5d20c"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000050", "text": "rubicin; TFIp, treatment-free interval from last platinum.\naPatient choice and quality-of-life issues may also suggest that platinum is not the best option.\nbIn patients with platinum intolerance who have relapsed >6 months from previous platinum, the combination of trabectedin and PLD may be recommended [II, C;\nESMO-MCBS v1.1 score: 2 for patients with platinum-sensitive disease; EMA approved, not FDA approved].\ncWeekly paclitaxel, PLD, topotecan or gemcitabine.\ndESMO-MCBS v1.1104 was used to calculate scores for new therapies/indications approved by the EMA or FDA. The scores have been calculated by the ESMO-MCBS\nWorking Group and validated by the ESMO Guidelines Committee (https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-evaluation-forms).\nePaclitaxel, PLD or gemcitabine (carboplatinegemcitabineebevacizumab: ESMO-MCBS v1.1 score: 3).d\nfUntil disease progression or next line of treatment is started [I, A].\ngOlaparib for BRCA1/2-mutated: ESMO-MCBS v1.1 score: 2;d niraparib regardless of BRCA1/2-mut status: ESMO-MCBS v1.1 score: 3;d rucaparib regardless of BRCA1/2-\nmut status: ESMO-MCBS v1.1 score: 3.d\nA. González-Martín et al.\nAnnals of Oncology\nVolume 34", "section": "Cochrane", "page_from": 9, "page_to": 9, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "5f4e03498e3b3dba8154d7a8118aad04f4c1b4d9041aa0b08017fe318e8c28cc"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000051", "text": "- Issue 10\n- 2023\nhttps://doi.org/10.1016/j.annonc.2023.07.011\n841", "section": "Cochrane", "page_from": 9, "page_to": 9, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "70b0a17419d589e6bfa7b9eecf44c52b5d568a6e1b43a7eb984183d8dc5c8576"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000052", "text": "In phase III trials, bevacizumab was administered until\nprogression or unacceptable toxicity occurred. Treatment\nshould be maintained until clinical or radiological progres-\nsion and should not be discontinued based solely on rising\nCA-125.\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nPARPis. Three PARPis (olaparib, niraparib and rucaparib) are\napproved for maintenance therapy of patients with high-\ngrade tubo-ovarian carcinoma that achieve a response to\nplatinum rechallenge, irrespective of BRCA1/2-mut or HRD\nstatus. Details of the outcome from four randomised trials\n(Study 19, SOLO2, NOVA and ARIEL3) are given in the\nSupplementary Material Section 4, available at https://doi.\norg/10.1016/j.annonc.2023.07.011.\nThe recommended length of PARPi treatment remains un-\nclear. In NOVA and ARIEL3 treatment was stopped at pro-\ngression, but in Study 19 and SOLO2 patients were allowed to\ncontinue olaparib beyond progression, if it was considered\nbeneﬁcial. From a clinical perspective, treatment beyond dis-\nease progression may have particular value in slow-growing", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3c3500ad6a97dbadc200ba3b7c2df49087b2df4c4fc8c577c74b1207ab24ed41"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000053", "text": "continue olaparib beyond progression, if it was considered\nbeneﬁcial. From a clinical perspective, treatment beyond dis-\nease progression may have particular value in slow-growing\ntumours or in the context of oligometastatic disease (e.g.\nsingle site of progression). All trials have shown that there is a\nsmall group of ‘super-responder’ patients (w10%) without\nprogression after 5 years on treatment with PARPis.\nRecently, data on OS after maintenance therapy raised\nconcern about a possible detrimental effect of PARPis,\nparticularly for non-gBRCA1/2-mut carriers. The OS ana-\nlyses, however, were secondary and underpowered end-\npoints. Long-term OS data from the NOVA trial and interim\nsurvival analysis of the NORA study have not categorically\nconﬁrmed the initial concern.81,82 Intermediate endpoints\nsuch as PFS2 (time to second subsequent therapy) or death\nsuggest a continuing beneﬁt from PARPis beyond progres-\nsion. Nevertheless, an exploratory analysis in SOLO2 sug-\ngested that gBRCA1/2-mut carriers who received olaparib\nhad a poorer response to platinum-based therapy on sub-\nsequent relapse,83 raising the hypothesis that PARPis may", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "243ecdbf4281697c255838beffa827982e3df376ea3eb5e5581f051225c4e339"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000054", "text": "gested that gBRCA1/2-mut carriers who received olaparib\nhad a poorer response to platinum-based therapy on sub-\nsequent relapse,83 raising the hypothesis that PARPis may\nencourage platinum resistance. The licence for use of\nPARPis has not been changed by the European Medicines\nAgency (EMA), but has been withdrawn by the Food and\nDrug Administration (FDA) for niraparib and rucaparib (but\nnot olaparib) in non-gBRCA1/2-mut carriers. It is advisable,\ntherefore, to have a discussion with patients without a\nBRCA1/2-mut about the beneﬁts and risks of PARPis.\nThere is currently no approval for pre-treatment with a\nPARPi. One trial, OREO/ENGOT-OV38, showed a positive\nshort-lived\nbeneﬁt\nfor\nsome\npatients\nretreated\nwith\nolaparib.84\nToxicity of PARPis is generally manageable through dose\nindividualisation (for niraparib), dose reductions and dose\ninterruptions. The rate of acute myeloid leukaemia and\nmyelodysplastic syndromes is higher among gBRCA1/2-\nmutated patients and in the recurrent setting compared\nwith ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "dfddca2e5599ec79a8cbe137bc7d77816e15aae7a85c807c92b184abe1b71de0"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000055", "text": "with ﬁrst line. This can probably be explained by an accu-\nmulative exposure to platinum.85\nSeveral factors need to be taken into consideration for\nthe selection of PARPis or anti-VEGF therapies in relapse\nincluding histotype, BRCA1/2-mut status, prior therapies\n(PARPi and/or bevacizumab), expected response to plat-\ninum ChT, presence of symptoms (speciﬁcally ascites),\npersistent toxicities from prior therapies, no contraindica-\ntion to bevacizumab and patient preference. Generally, for\nsymptomatic patients requiring a rapid treatment response,\nthe combination of carboplatin with bevacizumab would be\nrecommended (Figure 3).\nFurther information is provided in the Supplementary\nMaterial Section 4, available at https://doi.org/10.1016/j.\nannonc.2023.07.011.\nSystemic therapy when platinum is not an option\nFor some patients with recurrent ovarian cancer, platinum\nrechallenge may not be considered clinically appropriate.\nFor these patients, alternative systemic treatments are\navailable. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "3b1310cbe6a83f9e06c0eefcda9562e5749267fab5db557b68461e76b6c45435"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000056", "text": "available. Patients with good performance status should be\nprioritised for novel therapies within clinical trials. Inte-\ngrating early palliative care is particularly crucial.\nNon-platinum ChT options. Single-agent non-platinum ChT\nregimens include weekly paclitaxel, topotecan, gemcitabine,\nPLD and oral metronomic cyclophosphamide. These have\nshown modest activity in patients with relapsed ovarian\ncancer for whom platinum is not an option, with 10%-15%\nobjective response rate and median OS of 10-12 months.86-90\nWith regard to selecting a particular regimen, there are no\nrobust randomised data to support one agent over another,\nand not all are licensed for this indication. The choice should\nbe guided by patient preference and toxicity proﬁle. The\noptimal duration of treatment is unclear; in clinical trials, ChT\nwith non-platinum agents was planned until tumour pro-\ngression or unacceptable toxicity.\nTrabectedinePLD is approved in Europe for patients re-\nlapsing >6 months after last platinum.91 This combination\nis an option when such patients are ineligible for further\nplatinum.\nData\nwith\nantibody-drug\nconjugates\nhave\nshown\nencouraging results (see Supplementary Material Section 4,", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "96f8ec54b499b72f3df2fd2d1ab2fe2330037a09b95574b57a61da60cb92d263"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000057", "text": "is an option when such patients are ineligible for further\nplatinum.\nData\nwith\nantibody-drug\nconjugates\nhave\nshown\nencouraging results (see Supplementary Material Section 4,\navailable at https://doi.org/10.1016/j.annonc.2023.07.011).\nAntiangiogenic therapy. The addition of bevacizumab to\nsecond- or third-line non-platinum ChT (paclitaxel, PLD or\ntopotecan) in the AURELIA trial demonstrated an improve-\nment in median PFS, tumour response rate and QoL scores\ncompared with ChT alone.92 Notably, this trial excluded all\npatients at increased risk of intestinal ﬁstulae (progression\nduring ﬁrst-line platinum, history of bowel obstruction or\nserosal invasion), and <10% of patients had been previ-\nously exposed to bevacizumab.\nSystemic therapy for non-high-grade subtypes\nLess common histological subtypes such as CCC, carcino-\nsarcoma or LGSC are known to be less responsive to ChT\nincluding platinum.93 For these patients, once platinum is\nno longer an option, participation in clinical trials is strongly\nAnnals of Oncology\nA. González-Martín et al.\n842\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "8fedfd372790059739a89be7e608311d049eb16312e2f6771c0f45ec760ed789"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000058", "text": "- Issue 10\n- 2023", "section": "CA-125.", "page_from": 10, "page_to": 10, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e2817dc6eaff267531b67926a7522ca9be65b4d0d6cf18f509b4daa14ba9efd"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000059", "text": "recommended.94 For LGSC, one randomised phase III trial\ndemonstrated signiﬁcantly improved PFS and response rate\nfor the mitogen-activated protein kinase kinase (MEK) in-\nhibitor trametinib compared with standard of care (single-\nagent ChT or hormonal therapy at the choice of the inves-\ntigator).95 Another phase III trial with binimetinib, however,\ndid not have a positive result.96 These slowly proliferating\ntumours frequently express ER and/or PgR, and although\nobjective tumour responses are low, hormonal therapies\ncan be used to control tumour growth (e.g. aromatase\ninhibitors,\ntamoxifen\nor\nluteinising\nhormone-releasing\nhormone agonists).\nRecommendations\n\u0004 The following should be assessed when selecting treatment\nfor patients with recurrent disease [I-III, A]:\no Histotype\no BRCA1/2-mut status\no Number of prior lines of treatment\no Exposure and response to prior treatment\no TFIp\no Possibility of achieving a complete secondary surgical\ncytoreduction\no Residual ChT toxicity\no The patient’s general condition and preferences\n\u0004 Patients with ﬁrst relapse of ovarian cancer after >6\nmonths of last platinum administration should be evalu-", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "75e48d0bd16ee25b0732b6caf7967fcc20f4c42539c8918eb08dbd9257c19485"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000060", "text": "cytoreduction\no Residual ChT toxicity\no The patient’s general condition and preferences\n\u0004 Patients with ﬁrst relapse of ovarian cancer after >6\nmonths of last platinum administration should be evalu-\nated by a gynaecological oncology centre experienced in\nsurgery for ovarian cancer to identify potential candi-\ndates for surgical cytoreduction [I, A].\n\u0004 Patients who have previously responded to platinum\nwithout early symptomatic relapse should be treated\nwith either a platinum-based doublet (PLD, gemcitabine\nor paclitaxel) with bevacizumab [I, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3]\nor a platinum-based doublet followed by maintenance\nwith PARPi therapy if a response is achieved and the\npatient has not been previously exposed to PARPis\n[I, A; olaparib for BRCA1/2-mutated: ESMO-MCBS v1.1\nscore: 2; niraparib regardless of BRCA1/2-mut status:\nESMO-MCBS v1.1 score: 3; rucaparib regardless of\nBRCA1/2-mut status: ESMO-MCBS v1.1 score: 3].\n\u0004 For patients requiring rapid response, the combination\nof a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9214138900d5e6fc84a32c71eb1876c61e92c5158f3c1a83e08e91e609615041"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000061", "text": "of a platinum-based doublet (PLD, gemcitabine or pacli-\ntaxel) with bevacizumab is preferred [V, A; carboplatine\ngemcitabineebevacizumab ESMO-MCBS v1.1 score: 3].\n\u0004 Bevacizumab should be continued until disease progres-\nsion (symptomatic) or the next line of treatment is\nstarted, as continuation of bevacizumab beyond progres-\nsion has not been evaluated in the recurrent setting\n[I, A].\n\u0004 PARPis should be continued until disease progression or\nthe next line of treatment is started [I, A], as the beneﬁt\nof continuing treatment beyond progression has not\nbeen demonstrated conclusively to date [III, B].\n\u0004 Platinum rechallenge following treatment with a non-\nplatinum regimen (monotherapy or combination) could\nbe considered if the tumour did not progress during\nprior platinum therapy [III, B].\n\u0004 Patients with relapsed EOC for whom platinum is not an\noption should be deﬁned by [II-IV, A]:\no Proven resistance (progression during platinum)\no Expected resistance (early symptomatic progression\npost-platinum, response to rechallenge unlikely)\no Platinum intolerance\no Patient choice\no QoL issues\n\u0004 For patients not candidates to receive platinum, inte-", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e0c10f5679125bd93c0c0c38df7bf27a3256bbf226835eef131d32e939bcf13b"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000062", "text": "post-platinum, response to rechallenge unlikely)\no Platinum intolerance\no Patient choice\no QoL issues\n\u0004 For patients not candidates to receive platinum, inte-\ngrating palliative care early in the treatment pathway\nis strongly recommended [I, A].\n\u0004 Single-agent non-platinum options that can be recom-\nmended include weekly paclitaxel, PLD, topotecan and\ngemcitabine [I, B].\n\u0004 In patients with platinum intolerance who have relapsed\n>6 months from previous platinum, trabectedinePLD\nmay be recommended [II, C; ESMO-MCBS v1.1 score: 2\nfor\npatients\nwith\nplatinum-sensitive\ndisease;\nEMA\napproved, not FDA approved].\n\u0004 Bevacizumab should be recommended in combination\nwith weekly paclitaxel, PLD or topotecan in patients\nwithout contraindications to bevacizumab and not previ-\nously exposed to bevacizumab [I, A; ESMO-MCBS v1.1\nscore: 4].\n\u0004 Hormonal therapy is recommended for relapsed LGSC\n[II, A].\n\u0004 For patients with recurrent LGSC, treatment with the\nMEK inhibitor trametinib should be considered after\nprior platinum-based ChT and hormone therapy (not\nEMA approved) [I, A].\nFOLLOW-UP, LONG-TERM IMPLICATIONS AND\nSURVIVORSHIP\nSurveillance", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "ee0f2f7d68fa9424364908723eb9442385fc7cf56cbdce4264bb7bbb263051b6"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000063", "text": "MEK inhibitor trametinib should be considered after\nprior platinum-based ChT and hormone therapy (not\nEMA approved) [I, A].\nFOLLOW-UP, LONG-TERM IMPLICATIONS AND\nSURVIVORSHIP\nSurveillance\nAlthough a cure is unlikely after relapse, effective therapies\nexist for the treatment of patients with recurrent ovarian\ncancer. Therefore, surveillance in these patients is indicated\nwith a combination of thorough symptom review and\nphysical examination. Studies have noted that 26%-50% of\nrecurrences are in the pelvis97 suggesting a role for pelvic\nexamination in the follow-up of ovarian cancer. Disease\nrecurrence, however, may be located outside of the pelvis,\ne.g. in lymph nodes, liver, lungs or peritoneal carcinoma-\ntosis and may not be detectable by pelvic examination. CT\nscans have been noted to have a sensitivity of 79% and\nspeciﬁcity of 84% for detecting relapse in a large pooled\nmeta-analysis.98 CT scans are indicated if symptoms suggest\nrecurrent disease or if the CA-125 is rising.98\nCA-125 has been evaluated in the surveillance of ovarian\ncancer and has been noted to be elevated 2-5 months\nbefore radiographic detection of cancer. In a large pro-", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "acd1f34b1bd02bc66715446355573db5f2e4a70deff420cfd18f49a83d6d7269"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000064", "text": "CA-125 has been evaluated in the surveillance of ovarian\ncancer and has been noted to be elevated 2-5 months\nbefore radiographic detection of cancer. In a large pro-\nspective phase III Medical Research Council UK OV05/\nEORTC 55955 trial, there was no difference in OS when ChT\nwas initiated based solely on rising CA-125 levels versus\nA. González-Martín et al.\nAnnals of Oncology\nVolume 34", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "bab2394b9c4bae21f7c5d1c645f7741f58b7fd8fe59f82df99eedc3dab6334ed"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000065", "text": "- Issue 10\n- 2023\nhttps://doi.org/10.1016/j.annonc.2023.07.011\n843", "section": "CA-125.", "page_from": 11, "page_to": 11, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "a59bbf295ed36077d4558f0972bc6fc10fea5e39b822469bfae67256e04abea7"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000066", "text": "when disease recurrence had become clinically evident.99\nThe beneﬁt of surveillance with CA-125 in the current\neradwhen more sensitive radiological detection methods\nsuch as PETeCT and complete secondary cytoreduction and\ntargeted therapy have been shown to improve out-\ncomesdhas yet to be deﬁned.\nBRCA1/2-mut carriers and survival\nAlthough surveillance is generally undertaken for 5 years\nafter the most recent remission, longer follow-up may be\nconsidered in BRCA1/2-mut carriers, given their improved\nlong-term survival and need for breast cancer surveillance.\nIn a pooled analysis of 1213 EOC cases with pathogenic\ngBRCA1-mut (n ¼ 909) or gBRCA2-mut (n ¼ 304) and of\n2666 non-carriers, an improved 5-year OS was noted among\nBRCA1/2-mut carriers with ovarian cancer.100 A more recent\nreport of 15-year survival data in BRCA1/2-mut carriers\nsuggests that the survival beneﬁt appears to be within the\nﬁrst 5 years and decreases over time.101\nRecommendations\n\u0004 Surveillance of ovarian cancer patients can include CA-\n125 determination, physical examination and CT scan\nevaluation [IV, B].\n\u0004 BRCA1/2-mut carriers can be considered for follow-up\nbeyond 5 years [III, B].", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "f7aae7f62b21165d09efb9e02d84a27735b76e3172d5868ee2683241800597e7"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000067", "text": "125 determination, physical examination and CT scan\nevaluation [IV, B].\n\u0004 BRCA1/2-mut carriers can be considered for follow-up\nbeyond 5 years [III, B].\n\u0004 Long-term BRCA1/2-mut survivors should be referred to\nhigh-risk breast cancer clinics for follow-up [I, A].102\nMETHODOLOGY\nThis Clinical Practice Guideline (CPG) was developed in\naccordance with the ESMO standard operating procedures\nfor CPG development (https://www.esmo.org/Guidelines/\nESMO-Guidelines-Methodology). The\nrelevant\nliterature\nhas been selected by the expert authors. A table of ESCAT\nscores is included in Supplementary Table S2, available\nat\nhttps://doi.org/10.1016/j.annonc.2023.07.011.\nESCAT\nscores have been deﬁned by the authors, assisted if needed\nby the ESMO Translational Research and Precision Medicine\nWorking Group.103 A table of ESMO-MCBS scores is\nincluded in Supplementary Table S3, available at https://\ndoi.org/10.1016/j.annonc.2023.07.011.\nESMO-MCBS\nv1.1104 was used to calculate scores for new therapies/in-\ndications approved by the EMA or FDA (https://www.esmo.\norg/Guidelines/ESMO-MCBS). The scores have been calcu-\nlated by the ESMO-MCBS Working Group and validated by", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e33c9a4988dfeeb7589c0351fe747316ef14ab2fa4aad14fd76424c5c3f6d3a2"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000068", "text": "dications approved by the EMA or FDA (https://www.esmo.\norg/Guidelines/ESMO-MCBS). The scores have been calcu-\nlated by the ESMO-MCBS Working Group and validated by\nthe ESMO Guidelines Committee. The FDA/EMA or other\nregulatory body approval status of new therapies/in-\ndications is reported at the time of writing this CPG. Levels\nof evidence and grades of recommendation have been\napplied using the system shown in Supplementary Table S4,\navailable\nat\nhttps://doi.org/10.1016/j.annonc.2023.07.\n011.105 Statements without grading were considered justi-\nﬁed standard clinical practice by the authors. For future\nupdates to this CPG, including eUpdates and Living Guide-\nlines, please see the ESMO Guidelines website: https://\nwww.esmo.org/guidelines/guidelines-by-topic/gynaecological-\ncancers/newly-diagnosed-and-relapsed-epithelial-ovarian-\ncancer.\nACKNOWLEDGEMENTS\nManuscript editing support was provided by Ioanna Ntai,\nCatherine Evans, Claire Bramley and Jennifer Lamarre (ESMO\nGuidelines staff); this support was funded by ESMO. Nathan\nCherny, Chair of the ESMO-MCBS Working Group, and Ura-\nnia Dafni, Giota Zygoura, Georgia Dimopoulou and Tereza", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "45d95c0286b4c2e045b286a8f2b72c1868e3e037232689a3c306d14ed3a0566e"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000069", "text": "Guidelines staff); this support was funded by ESMO. Nathan\nCherny, Chair of the ESMO-MCBS Working Group, and Ura-\nnia Dafni, Giota Zygoura, Georgia Dimopoulou and Tereza\nDellaporta of Frontier Science Foundation Hellas provided\nreview and validation of the ESMO-MCBS scores. Nicola\nLatino (ESMO Scientiﬁc Affairs staff) provided coordination\nand support of the ESMO-MCBS scoring and Angela Cor-\nstorphine of Kstorﬁn Medical Communications Ltd provided\nmedical writing and editing support in the preparation of the\nESMO-MCBS table; this support was funded by ESMO.\nDr Svetlana Jezdic (ESMO Medical Affairs staff) provided\ncoordination and support of the ESCAT scoring.\nFUNDING\nNo external funding has been received for the preparation\nof this guideline. Production costs have been covered by\nESMO from central funds.\nDISCLOSURE\nAGM reports personal fees for advisory board membership\nfrom Alkermes, Amgen, AstraZeneca, Clovis Oncology, Eisai,\nGenmab, GSK, HederaDx, Illumina, ImmunoGen, Macro-\nGenics, Mersana, MSD, Novartis, Oncoinvent, PharmaMar,\nRegeneron, Roche, SOTIO, Sutro Biopharma and Tubulis;\npersonal fees as an invited speaker from AstraZeneca, Clovis", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7be4f4d01e54de8530fcbd23753e469b8f3b2a37ffc1ab896221385016228f15"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000070", "text": "Genics, Mersana, MSD, Novartis, Oncoinvent, PharmaMar,\nRegeneron, Roche, SOTIO, Sutro Biopharma and Tubulis;\npersonal fees as an invited speaker from AstraZeneca, Clovis\nOncology, GSK, MSD, Novocure, Roche, Takeda and Zai Lab;\ninstitutional funding as coordinating principal investigator\n(PI) from Aravive, GSK, Novartis and Roche; and a non-\nremunerated role as Steering Committee Member for\nMSD. PH reports personal fees for advisory board mem-\nbership from AstraZeneca, Clovis Oncology, GSK, Immu-\nnoGen, Mersana, Miltenyi, MSD, Novartis and Roche;\npersonal fees as an invited speaker from Amgen, Eisai,\nStryker and Zai Lab; personal fees for lectures from Astra-\nZeneca, GSK, MSD and Roche; personal fees as an Inde-\npendent Data Monitoring Committee (IDMC) member from\nSOTIO; institutional funding as Trial Chair from AstraZeneca,\nGSK, ImmunoGen and Roche; institutional funding as local\nPI from Genmab; institutional funding from Clovis Oncology\nand Seagen; and a non-remunerated role as PI from\nAstraZeneca. AL reports personal fees for advisory board\nmembership from Zentalis Pharmaceuticals; personal fees\nas an invited speaker from GSK and Medscape; personal", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "e3061f896c1b86d268c753cdd54a06736bdb2e254028261302f1c4d902d84b8e"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000071", "text": "AstraZeneca. AL reports personal fees for advisory board\nmembership from Zentalis Pharmaceuticals; personal fees\nas an invited speaker from GSK and Medscape; personal\nfees for consultancy from GLG; personal fees for a writing\nengagement from Onkoþ; fees paid to her institute for\nadvisory board membership from Ability Pharma, Apmonia,\nAstraZeneca, Blueprint, Clovis Oncology, GSK, Merck Serono\nand MSD; fees paid to her institute as an invited speaker\nfrom AstraZeneca, Clovis Oncology and Kephren Publishing;\nfees paid to her institute for consultancy from Orion and\nAnnals of Oncology\nA. González-Martín et al.\n844\nhttps://doi.org/10.1016/j.annonc.2023.07.011\nVolume 34", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "79aab8f0f106fed721540ebb5d6be5b3ce5553fb0ce53c15f79223c4bb04f774"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000072", "text": "- Issue 10\n- 2023", "section": "CA-125.", "page_from": 12, "page_to": 12, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "7e2817dc6eaff267531b67926a7522ca9be65b4d0d6cf18f509b4daa14ba9efd"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000073", "text": "Owkin; fees paid to her institute for steering committee\nmembership from MSD; institutional funding as a PI in\nclinical trials from Agenus, AstraZeneca, Bristol Myers\nSquibb (BMS), GSK, Iovance; MSD and Roche; institutional\nfunding as a Chief Investigator in clinical trials from Astra-\nZeneca and OSE Immunotherapeutics; institutional research\ngrants as a PI in translational research from ARCAGY-\nGINECO, AstraZeneca and Sanoﬁ; a non-remunerated role\nas an IDMC member for Clovis Oncology, as an IDMC Chair\nfor Pﬁzer (proprietary information) and as a member of the\nGCIG; and non-remunerated academic research projects for\nLXRepair and Owkin. DL reports personal fees for advisory\nboard membership from AstraZeneca, Clovis Oncology,\nCorcept, Genmab, GSK, ImmunoGen, MSD, Oncoinvest,\nPharmaMar, Seagen and Sutro Biopharma; personal fees as\nan invited speaker from AstraZeneca, Clovis Oncology,\nGenmab, GSK, ImmunoGen, MSD, PharmaMar and Seagen;\npersonal fees for consultancy from AstraZeneca, Clovis\nOncology, Genmab, GSK, ImmunoGen, MSD, Novartis,\nPharmaMar and Seagen; travel grants from AstraZeneca,\nClovis Oncology and GSK; institutional funding as coordi-", "section": "CA-125.", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "4470d9588f054203778181a1d864313d1258de32506adb9dfa3275a9b8c69f5c"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000074", "text": "Oncology, Genmab, GSK, ImmunoGen, MSD, Novartis,\nPharmaMar and Seagen; travel grants from AstraZeneca,\nClovis Oncology and GSK; institutional funding as coordi-\nnating PI from Clovis Oncology, Genmab and MSD; institu-\ntional funding for a clinical trial/contracted research from\nAstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen,\nIncyte, MSD, Novartis, Roche and Seagen; institutional\nfunding\nfor\nfounding\nan\nacademic\ntrial\nfrom\nClovis\nOncology, GSK, MSD and PharmaMar; a non-remunerated\nrole as a PI in clinical trials for AstraZeneca, Clovis\nOncology,\nGenmab,\nGSK,\nImmunoGen,\nIncyte,\nMSD,\nNovartis, PharmaMar, Roche and Seagen; and a non-\nremunerated role as a member of the Board of Directors\nof GCIG. REM reports personal fees for advisory board\nmembership from AstraZeneca, GSK and Merck; personal\nfees as an invited speaker from AstraZeneca, Clovis\nOncology and GSK; and personal fees for expert testimony\nfrom Ellipses and Shionogi. BP reports personal fees for\nadvisory\nboard membership from\nAstraZeneca,\nClovis\nOncology, Eisai, GSK, GOG Foundation, Lilly, Merck, Mer-\nsana, Seattle Genetics, Sutro and Tesaro; personal fees for\nconsulting from Arquer Diagnostics, Atossa, Bioascend,", "section": "CA-125.", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9d93faed912c75d45e13038ea576418e16f7bc3ab877a902bce75bbbbb4f1880"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000075", "text": "AstraZeneca,\nClovis\nOncology, Eisai, GSK, GOG Foundation, Lilly, Merck, Mer-\nsana, Seattle Genetics, Sutro and Tesaro; personal fees for\nconsulting from Arquer Diagnostics, Atossa, Bioascend,\nDeciphera, Elevar, Imab, Onclive, Onconova Therapeutics,\nPeerView, Toray and WebMD; institutional funding as local\nPI from Acrivon, AstraZeneca, Celgene, Celsion, Clovis\nOncology, Eisai, GSK, ImmunoGen, Incyte, Karyopharm,\nMerck, Mersana, Roche Genentech, Seattle Genetics, Sutro,\nTakeda, Tesaro, Toray and VBL Therapeutics; membership of\nthe GOG Partners group at the GOG Foundation; and\nmembership of the Board of Directors of the Society of\nGynecologic Oncology (SGO). IRC reports personal fees for\nadvisory board membership from Adaptimmune, Agenus,\nAmgen, AstraZeneca, BMS, Clovis Oncology, Daiichi Sankyo,\nDeciphera, EQRX, Eisai, GSK, MacroGenics, Merck Sereno,\nMersana, Novartis, Oxnea, Roche and Sutro Biopharma;\nfees paid to her institute for advisory board membership\nfrom MSD; fees paid to her institute for translational\nresearch from BMS; a non-remunerated role as President of\nGINECO; and a non-remunerated role as PI for PAOLA-1.\nDSPT\nreports\npersonal\nfees\nfor\nadvisory\nboard", "section": "CA-125.", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "9bef50f3d9103c582959f1ad96deb644c75b4f088a303f57e3a1c8a7279dfabe"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000076", "text": "research from BMS; a non-remunerated role as President of\nGINECO; and a non-remunerated role as PI for PAOLA-1.\nDSPT\nreports\npersonal\nfees\nfor\nadvisory\nboard\nmembership from AstraZeneca, Bayer, Boehringer Ingel-\nheim, Eisai, Genmab, GSK, MSD and Roche; personal fees as\nan invited speaker from AstraZeneca, Eisai, GSK, Merck\nSerono, MSD, Roche and Takeda; ownership of stocks/\nshares of Asian Microbiome Library (AMiLi); institutional\nresearch grants from AstraZeneca, Bayer, Karyopharm\nTherapeutics and Roche; institutional funding as coordi-\nnating PI from AstraZeneca and Bergen Bio; institutional\nfunding as local PI from Bayer, Byondis B.V. and Zeria\nPharmaceutical Co Ltd; a previous non-renumerated role as\nChair of the Asia-Paciﬁc Gynecologic Oncology Trials Group\n(APGOT); a previous non-renumerated role as the Society\nPresident of the Gynecologic Cancer Group Singapore; non-\nrenumerated membership of the Board of Directors of the\nGCIG; and product samples from AstraZeneca, Cyclacel\nPharmaceuticals, Eisai and MSD (non-ﬁnancial interest). EB\ndeclares no conﬂicts of interest. AO reports personal fees\nfor advisory board membership from Agenus, AstraZeneca,", "section": "CA-125.", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "c145c369c8d089628e071c0f860ed039eaf81287657bd797b2fcde7ec55c2c96"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000077", "text": "Pharmaceuticals, Eisai and MSD (non-ﬁnancial interest). EB\ndeclares no conﬂicts of interest. AO reports personal fees\nfor advisory board membership from Agenus, AstraZeneca,\nClovis Oncology, Corcept Therapeutics, Deciphera Pharma-\nceuticals, Eisai, Exelisis, EMD Serono, F. Hoffmann-La Roche,\nGenmab, GSK, ImmunoGen, Itheos, Merck Sharps & Dohme\nde España, SA, Mersana Therapeutics, Novocure, OncXerna\nTherapeutics, Inc., PharmaMar, Regeneron, Sattucklabs,\nSeagen and Sutro Biopharma; personal fees for travel/ac-\ncommodation from AstraZeneca, PharmaMar and Roche;\ninstitutional funding from Abbvie Deutschland, Advaxis Inc.,\nAeterna Zentaris, Amgen, Aprea Therapeutics AB, BMS,\nClovis Oncology Inc, Eisai Co, Ltd, F. Hoffmann-La Roche Ltd,\nImmunoGen Inc, Merck, Sharp & Dohme de España SA,\nMillennium Pharmaceuticals Inc, PharmaMar SA, Regeneron\nPharmaceuticals and Tesaro Inc.; non-remunerated roles at\nESMO (member, Ofﬁcer, Co-Chair of the ESMO Gynaeco-\nlogical Cancers Congress 2023-2025, Chair of the Gynaeco-\nlogical\nTrack\nESMO\n2019,\nScientiﬁc\nTrack\nMember\nGynaecological Cancers ESMO 2018, ESMO 2020, ESMO\n2022, member of the Gynaecological Cancers Faculty and", "section": "CA-125.", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "46ea27b1835207e66232898bb28829bb06641db9849e86762916c7bc6099e629"}
{"doc_id": "esmo_cpg_epithelialovarian_2023__v00000000", "chunk_id": "000078", "text": "logical\nTrack\nESMO\n2019,\nScientiﬁc\nTrack\nMember\nGynaecological Cancers ESMO 2018, ESMO 2020, ESMO\n2022, member of the Gynaecological Cancers Faculty and\nSubject Editor for the Gynaecological CPGs); a non-\nremunerated role at GCIG (member and Cervix Cancer\nChair on behalf of GEICO); and membership of ASCO, GOG\nand SEOM. JAL reports personal fees for advisory board\nmembership for Artios Pharma, AstraZeneca, BMS, Clovis\nOncology, Eisai, Ellipses, GSK, Immagene, ImmunoGen,\nMerck/MSD, Miltenyi, Novocure, Nuvation and VBL Thera-\npeutics; personal fees as an invited speaker from AstraZe-\nneca, Clovis Oncology, GSK and Neopharm; personal fees as\nan IDMC member from Mersana and Sutro Bio; a remu-\nnerated leadership role as an Associate Editor of Thera-\npeutic Advances in Medical Oncology (Sage Publishing);\ninstitutional research grants from AstraZeneca and MSD/\nMerck; non-remunerated roles at ESMO (Ofﬁcer and Sub-\nject Editor for the Gynaecological CPGs); and a non-\nremunerated leadership role as Vice-President of ESGO\n(2019-2021).", "section": "CA-125.", "page_from": 13, "page_to": 13, "display_name": "ESMO_CPG_EpithelialOvarian_2023", "version": "v00000000", "created_at": "2025-11-28T05:59:44", "hash": "6c33fc7b93c1803daec19014662784af29d9a300142c131784fafb6a4f21c287"}
